DNA hypermethylation status of multiple genes in soft tissue sarcomas
- PMID: 16258501
- DOI: 10.1038/modpathol.3800502
DNA hypermethylation status of multiple genes in soft tissue sarcomas
Abstract
The aberrant methylation of promoter CpG islands is known to be a major inactivation mechanism of tumor-related genes. To determine the clinicopathological significance of gene promoter methylation in soft tissue sarcomas, we examined the promoter methylation status of 10 tumor-related genes in 65 soft tissue sarcomas and 19 adjacent non-neoplastic tissues by methylation-specific PCR. The methylation frequencies of tumor-related genes tested in soft tissue sarcomas were 17 (26%) for RASSF1A, 11 (17%) for DAP kinase, 10 (15%) for MGMT, nine (14%) for GSTP1, eight (12%) for PTEN, six (9%) for p16 and hMLH1, five (8%) for hMSH2, two (3%) for p14, and one (2%) for RB. Promoter methylation of these genes was not recognized in non-neoplastic tissues. All those cases of soft tissue sarcoma that had MGMT methylation, with the exception of one case of malignant peripheral nerve sheath tumor, showed large tumor size (> or = 10 cm) or recurrence. Moreover, eight of 10 cases with MGMT methylation revealed high American Joint Committee on Cancer stage. Seven of 10 cases (70%) with MGMT methylation showed a loss of MGMT expression by immunohistochemistry. In addition, MGMT methylation status had a statistically significant correlation with a loss of MGMT expression (P=0.014). In conclusion, although methylation of tumor-related genes was a relatively rare event in soft tissue sarcomas, methylation was tumor-specific. Of 10 tumor-related genes, cases with MGMT methylation had a tendency to be aggressive behavior. Moreover, MGMT methylation was closely associated with a loss of MGMT expression. Although our findings need to be extending to a large series, promoter methylation of tumor-related genes is likely to have an association with the pathogenesis of soft tissue sarcomas. Furthermore, MGMT methylation may be associated with tumor aggressiveness and the inactivation of MGMT gene.
Similar articles
-
Promoter methylation status of hMLH1, hMSH2, and MGMT genes in colorectal cancer associated with adenoma-carcinoma sequence.Langenbecks Arch Surg. 2011 Oct;396(7):1017-26. doi: 10.1007/s00423-011-0812-9. Epub 2011 Jun 25. Langenbecks Arch Surg. 2011. PMID: 21706233
-
Promoter hypermethylation of DNA damage response genes in hepatocellular carcinoma.Cell Biol Int. 2012 May 1;36(5):427-32. doi: 10.1042/CBI20100851. Cell Biol Int. 2012. PMID: 21864295
-
Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma.Clin Cancer Res. 2002 Jan;8(1):131-7. Clin Cancer Res. 2002. PMID: 11801549
-
Gene methylation in gastric cancer.Clin Chim Acta. 2013 Sep 23;424:53-65. doi: 10.1016/j.cca.2013.05.002. Epub 2013 May 10. Clin Chim Acta. 2013. PMID: 23669186 Review.
-
Sarcoma diagnosis by DNA methylation classifier: A systematic review, current status and future prospects.Pathol Res Pract. 2024 Nov;263:155634. doi: 10.1016/j.prp.2024.155634. Epub 2024 Oct 4. Pathol Res Pract. 2024. PMID: 39383738 Review.
Cited by
-
Integrative DNA methylation and gene expression analysis in high-grade soft tissue sarcomas.Genome Biol. 2013 Dec 17;14(12):r137. doi: 10.1186/gb-2013-14-12-r137. Genome Biol. 2013. PMID: 24345474 Free PMC article.
-
DNA methylation: its role in cancer development and therapy.Curr Probl Cancer. 2008 Sep-Oct;32(5):187-235. doi: 10.1016/j.currproblcancer.2008.08.002. Curr Probl Cancer. 2008. PMID: 18926282 Free PMC article. Review. No abstract available.
-
A review of soft-tissue sarcomas: translation of biological advances into treatment measures.Cancer Manag Res. 2018 May 10;10:1089-1114. doi: 10.2147/CMAR.S159641. eCollection 2018. Cancer Manag Res. 2018. PMID: 29785138 Free PMC article. Review.
-
Aberrant methylation of different DNA repair genes demonstrates distinct prognostic value for esophageal cancer.Dig Dis Sci. 2011 Oct;56(10):2992-3004. doi: 10.1007/s10620-011-1774-z. Epub 2011 Jun 15. Dig Dis Sci. 2011. PMID: 21674174
-
MGMT promoter methylation and immunoexpression in aggressive pituitary adenomas and carcinomas.J Neurooncol. 2011 Sep;104(3):647-57. doi: 10.1007/s11060-011-0532-6. Epub 2011 Feb 11. J Neurooncol. 2011. PMID: 21311951
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous